Periodic Reporting for period 1 - BacTheRNA (Bacterial-Derived Therapeutics based on CircRNAs (BacTheRNA))
Reporting period: 2022-07-16 to 2024-05-15
Probiotic bacteria are beneficial to the host in several ways. The final goal of BacTheRNA is the development of novel RNA-based therapeutics using probiotic bacteria. These can be used as a biological production factory for RNA therapeutics, at a cheaper cost than chemical synthetic routes. Due to their being harmless and food-grade, they represent a safe and low-cost alternative to current methods.
This project was terminated early so it did not reach its full objectives and potential. However, in the months of implementation, preliminary results were achieved that could set the basis for further research. A suitable probiotic strain was selected, and DNA plasmids were designed (but not tested or validated) to perform subsequent experiments. Particular RNA targets naturally produced by these bacteria were also studied, yielding preliminary results.
Due to the short duration of the project, the impact could not be fully achieved. The results achieved are preliminary.